P
Piotr Lewczuk
Researcher at University of Erlangen-Nuremberg
Publications - 151
Citations - 10603
Piotr Lewczuk is an academic researcher from University of Erlangen-Nuremberg. The author has contributed to research in topics: Dementia & Disease. The author has an hindex of 49, co-authored 142 publications receiving 8991 citations. Previous affiliations of Piotr Lewczuk include Medical University of Białystok.
Papers
More filters
Journal ArticleDOI
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
Leslie M. Shaw,Hugo Vanderstichele,Malgorzata Knapik-Czajka,Christopher M. Clark,Paul S. Aisen,Ronald C. Petersen,Kaj Blennow,Holly Soares,Adam J. Simon,Piotr Lewczuk,Robert A. Dean,Eric Siemers,William Z. Potter,Virginia M.-Y. Lee,John Q. Trojanowski +14 more
TL;DR: Develop a cerebrospinal fluid biomarker signature for mild Alzheimer's disease (AD) in Alzheimer's Disease Neuroimaging Initiative (ADNI) subjects.
Journal ArticleDOI
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease.
TL;DR: Low cerebrospinal fluid concentrations of the amyloid‐β (Aβ1‐42) peptide, in combination with high total tau and phosphorylated tau, are sensitive and specific biomarkers highly predictive of progression to AD dementia in patients with mild cognitive impairment.
Journal ArticleDOI
The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers
Niklas Mattsson,Ulf Andreasson,Staffan Persson,Hiroyuki Arai,Sat Dev Batish,Sergio Bernardini,Luisella Bocchio-Chiavetto,Marinus A. Blankenstein,Maria Berrocal Carrillo,Sonia Chalbot,Els Coart,Davide Chiasserini,Neal Cutler,Gunilla Dahlfors,Stefan Duller,Anne M. Fagan,Orestes Vicente Forlenza,Giovanni B. Frisoni,Douglas Galasko,Daniela Galimberti,Harald Hampel,Aase Handberg,Michael T. Heneka,Adrianna Z. Herskovits,Sanna-Kaisa Herukka,David M. Holtzman,Christian Humpel,Bradley T. Hyman,Khalid Iqbal,Mathias Jucker,Stephan A. Kaeser,Elmar Kaiser,Elisabeth Kapaki,Daniel Kidd,Péter Klivényi,Cindy Soendersoe Knudsen,Markus P. Kummer,James Lui,Albert Lladó,Piotr Lewczuk,Qiao-Xin Li,Ralph N. Martins,Colin L. Masters,John McAuliffe,Marc Mercken,Abhay Moghekar,José Luis Molinuevo,Thomas J. Montine,William Nowatzke,Richard O'Brien,Markus Otto,George P. Paraskevas,Lucilla Parnetti,Ronald C. Petersen,David Prvulovic,Herman P M de Reus,Robert A. Rissman,Elio Scarpini,Alessandro Stefani,Hilkka Soininen,Johannes Schröder,Leslie M. Shaw,Anders Skinningsrud,Brith Skrogstad,Annette Spreer,Leda Leme Talib,Charlotte E. Teunissen,John Q. Trojanowski,Hayrettin Tumani,Robert M. Umek,Bianca Van Broeck,Hugo Vanderstichele,László Vécsei,Marcel M. Verbeek,Manfred Windisch,Jing Zhang,Henrik Zetterberg,Kaj Blennow +77 more
TL;DR: The cerebrospinal fluid biomarkers amyloid β (Aβ)‐42, total‐Tau (T‐tau), and phosphorylated‐t Tau (P‐tAU) demonstrate good diagnostic accuracy for Alzheimer's disease (AD), but there are large variations in biomarker measurements between studies, and between and within laboratories.
Journal ArticleDOI
A Practical Guide to Immunoassay Method Validation
Ulf Andreasson,Armand Perret-Liaudet,Linda J C van Waalwijk van Doorn,Kaj Blennow,Davide Chiasserini,Sebastiaan Engelborghs,Tormod Fladby,Sermin Genc,Niels Kruse,H. Bea Kuiperij,Luka Kulic,Piotr Lewczuk,Brit Mollenhauer,Barbara Mroczko,Lucilla Parnetti,Eugeen Vanmechelen,Marcel M. Verbeek,Bengt Winblad,Henrik Zetterberg,Henrik Zetterberg,Marleen J.A. Koel-Simmelink,Charlotte E. Teunissen +21 more
TL;DR: Standard operating procedures (SOPs) with step-by-step instructions for a number of different validation parameters is included in the present work together with a validation report template, which allow for a well-ordered presentation of the results.
Journal ArticleDOI
Update on the biomarker core of the Alzheimer's Disease Neuroimaging Initiative subjects
John Q. Trojanowski,Hugo Vandeerstichele,Magdalena Korecka,Christopher M. Clark,Paul S. Aisen,Ronald C. Petersen,Kaj Blennow,Holly Soares,Adam J. Simon,Piotr Lewczuk,Robert A. Dean,Eric Siemers,William Z. Potter,Michael W. Weiner,Clifford R. Jack,William J. Jagust,Arthur W. Toga,Virginia M.-Y. Lee,Leslie M. Shaw +18 more
TL;DR: Progress by the Penn Biomarker Core in the Alzheimer's Disease Neuroimaging Initiative (ADNI) toward developing a pathological cerebrospinal fluid and plasma biomarker signature for mild Alzheimer's disease as well as a biomarker profile that predicts conversion of mild cognitive impairment and/or normal control subjects to AD are reviewed.